Also known as: food allergies
Food allergy is an immune-mediated adverse health effect that occurs reproducibly after exposure to a specific food allergen. Reactions can range from mild symptoms to severe anaphylaxis, and management depends on strict allergen avoidance and emergency preparedness. Food allergy imposes substantial public-health and quality-of-life burden.
Slow up-dosing peanut OIT enabled 82% of toddlers to tolerate 3.5 peanuts after treatment. Low-dose OIT was safe in preschoolers with single or multiple food allergies. Allergist guidance on anxiety was linked to reduced caregiver worry.
Needle-free allergy therapy is forecast to expand through 2035 as self-administered options gain share. House dust mite allergy treatment is projected to grow from $3.18 billion in 2025 to $8.75 billion by 2033.
A study in the Journal of Experimental Medicine found that DOCK8 deficiency drives severe food allergies by expanding Tfh13 cells and reducing regulatory T-cells. The findings help explain why DOCK8 mutations, but not STAT3 mutations alone, consistently lead to elevated food-specific IgE and clinically significant reactions.
Pfizer's tilrekimig met its primary endpoint in a mid-stage eczema trial and will advance to late-stage testing. Separately, oral remibrutinib demonstrated rapid efficacy in treating peanut allergy in a phase II study.
Novartis announced positive topline results from its Phase III RemIND trial of remibrutinib in chronic inducible urticaria, meeting the primary endpoint for the three most prevalent types of the condition with significantly higher complete response rates versus placebo.
Novartis announced positive Phase III RemIND trial results for oral remibrutinib in chronic inducible urticaria, marking the first therapy to meet a Phase III primary endpoint in the condition. The company has submitted a supplemental New Drug Application to the FDA.
Novartis reported positive Phase III RemIND trial results showing remibrutinib achieved complete response in three types of chronic inducible urticaria. The company has submitted a supplemental New Drug Application to the FDA for symptomatic dermographism.
Novartis announced positive topline results from its pivotal Phase III RemIND trial of oral remibrutinib in chronic inducible urticaria, meeting the primary endpoint for three prevalent CIndU types with significantly higher complete response rates versus placebo at Week 12.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07321522 |
Early Introduction and Sustained Ingestion (EISI) Using Two Educational Opportunities in Infants |
NOT_YET_RECRUITING | NA |
| NCT07212530 |
EmoTIChealth: Promoting Adolescent Health Through a Serious Game. |
RECRUITING | NA |
| NCT07210320 |
PK/PD Study of IN-001 Sublingual Spray in Healthy Adults |
COMPLETED | PHASE1 |
| NCT07040111 |
Efficacy and Safety of Egg Ladders in Children With IgE-Mediated Hen's Egg Protein Allergy |
NOT_YET_RECRUITING | NA |
| NCT06943534 |
Omalizumab Weight-Based Dosing Efficacy Trial |
RECRUITING | PHASE2 |
| NCT06872996 |
Trophallergen Prick Tests (PT) : Influence of Food Sample Shelf Life on the Reproducibility of PT Results |
RECRUITING | NA |
| NCT06792838 |
Endomicroscopic Evaluation of Food-induced Gastrointestinal Mucosal Alteration |
NOT_YET_RECRUITING | NA |
| NCT06664918 |
Effectiveness and Safety of Milk Ladders in Children with IgE-Mediated Cow's Milk Protein Allergy |
RECRUITING | NA |
| NCT06652698 |
Early Supplementation for Cow's Milk Allergy Prevention |
NOT_YET_RECRUITING | NA |
| NCT06634992 |
Observatory of the Lille Paediatric Allergy Unit |
RECRUITING |
